Locally-delivered T-cell-derived cellular vehicles efficiently track and deliver adenovirus delta24-RGD to infiltrating glioma

Viruses

Volumn 6, Issue 8, 2014, Pages 3080-3096

  Balvers, Rutger K ^a   Belcaid, Zineb ^a   van den Hengel, Sanne K ^b   Kloezeman, Jenneke ^a   de Vrij, Jeroen ^a,b   Wakimoto, Hiroaki ^c   Hoeben, Rob C ^b   Debets, Reno ^d   Leenstra, Sieger ^a   Dirven, Clemens ^a   Lamfers, Martine L M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Cellular vehicles; Delta24 RGD; Glioblastoma; GSC; Oncolytic; T cell therapy; Virotherapy

Indexed keywords

ONCOLYTIC VIRUS;

ADENOVIRIDAE; ANIMAL; BIOLOGICAL THERAPY; CELL LINE; DISEASE MODEL; DRUG DELIVERY SYSTEM; FEMALE; GLIOMA; GROWTH, DEVELOPMENT AND AGING; HUMAN; MOUSE; PHYSIOLOGY; PROCEDURES; SURVIVAL; T LYMPHOCYTE; TREATMENT OUTCOME; VIROLOGY;

ADENOVIRIDAE; ANIMALS; BIOLOGICAL THERAPY; CELL LINE; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMALE; GLIOMA; HUMANS; MICE; ONCOLYTIC VIRUSES; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84906070126     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v6083080     Document Type: Article

References (48)

1. Huse, J.T.; Holland, E.C. Targeting brain cancer: Advances in the molecular pathology of malignant glioma and medulloblastoma. Nat. Rev. Cancer 2010, 10, 319-331.
2. Kroeger, K.M.; Muhammad, A.K.; Baker, G.J.; Assi, H.; Wibowo, M.K.; Xiong, W.; Yagiz, K.; Candolfi, M.; Lowenstein, P.R.; Castro, M.G. Gene therapy and virotherapy: Novel therapeutic approaches for brain tumors. Discov. Med. 2010, 10, 293-304.
3. Murphy, A.M.; Rabkin, S.D. Current status of gene therapy for brain tumors. Transl. Res. 2013, 161, 339-354.
4. Lang, F.F.; Bruner, J.M.; Fuller, G.N.; Aldape, K.; Prados, M.D.; Chang, S.; Berger, M.S.; McDermott, M.W.; Kunwar, S.M.; Junck, L.R.; et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: Biological and clinical results. J. Clin. Oncol. 2003, 21, 2508-2518.
5. Chiocca, E.A.; Broaddus, W.C.; Gillies, G.T.; Visted, T.; Lamfers, M.L.M. Neurosurgical delivery of chemotherapeutics, targeted toxins, genetic and viral therapies in neuro-oncology. J. Neurooncol. 2004, 69, 101-117.
6. Lamfers, M.L.; Grill, J.; Dirven, C.M.; van Beusechem, V.W.; Geoerger, B.; van Den Berg, J.; Alemany, R.; Fueyo, J.; Curiel, D.T.; et al. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res. 2002, 62, 5736-5742.
7. Jiang, H.; Gomez-Manzano, C.; Aoki, H.; Alonso, M.M.; Kondo, S.; McCormick, F.; Xu, J.; Kondo, Y.; Bekele, B.N.; Colman, H.; et al. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: Role of autophagic cell death. J. Natl. Cancer Inst. 2007, 99, 1410-1414.
8. Fueyo, J.; Alemany, R.; Gomez-Manzano, C.; Fuller, G.N.; Khan, A.; Conrad, C.A.; Liu, T.J.; Jiang, H.; Lemoine, M.G.; Suzuki, K.; et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J. Natl. Cancer Inst. 2003, 95, 652-660.
9. Suzuki, K.; Fueyo, J.; Krasnykh, V.; Reynolds, P.N.; Curiel, D.T.; Alemany, R. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin. Cancer Res. 2001, 7, 120-126.
10. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455, 1061-1068.
11. Grill, J.; van Beusechem, V.W.; van Der Valk, P.; Dirven, C.M.; Leonhart, A.; Pherai, D.S.; Haisma, H.J.; Pinedo, H.M.; Curiel, D.T.; Gerritsen, W.R. Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids. Clin. Cancer Res. 2001, 7, 641-650.
12. Jiang, H.; Gomez-Manzano, C.; Lang, F.F.; Alemany, R.; Fueyo, J. Oncolytic adenoviruses for malignant glioma therapy. Front. Biosci. 2003, 8, 577-588.
13. Tabatabai, G.; Wick, W.; Weller, M. Stem cell-mediated gene therapies for malignant gliomas: A promising targeted therapeutic approach? Discov. Med. 2011, 11, 529-536.
14. Willmon, C.; Harrington, K.; Kottke, T.; Prestwich, R.; Melcher, A.; Vile, R. Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol. Ther. 2009, 17, 1667-1676.
15. Yong, R.L.; Shinojima, N.; Fueyo, J.; Gumin, J.; Vecil, G.G.; Marini, F.C.; Bogler, O.; Andreeff, M.; Lang, F.F. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res. 2009, 69, 8932-8940.
16. Ahmed, A.U.; Tyler, M.A.; Thaci, B.; Alexiades, N.G.; Han, Y.; Ulasov, I.V.; Lesniak, M.S. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. Mol. Pharm. 2011, 8, 1559-1572.
17. Xia, X.; Ji, T.; Chen, P.; Li, X.; Fang, Y.; Gao, Q.; Liao, S.; You, L.; Xu, H.; Ma, Q.; et al. Mesenchymal stem cells as carriers and amplifiers in CRAd delivery to tumors. Mol. Cancer 2011, 10, 134.
18. Ahmed, A.U.; Thaci, B.; Tobias, A.L.; Auffinger, B.; Zhang, L.; Cheng, Y.; Kim, C.K.; Yunis, C.; Han, Y.; Alexiades, N.G.; et al. A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy. J. Natl. Cancer Inst. 2013, 105, 968-977.
19. Tyler, M.A.; Ulasov, I.V.; Sonabend, A.M.; Nandi, S.; Han, Y.; Marler, S.; Roth, J.; Lesniak, M.S. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther. 2009, 16, 262-278.
20. Kim, C.K.; Ahmed, A.U.; Auffinger, B.; Ulasov, I.V.; Tobias, A.L.; Moon, K.S.; Lesniak, M.S. N-acetylcysteine amide (NACA) Augments the Therapeutic Effect of Neural Stem Cell.-Based Anti-Glioma Oncolytic Virotherapy. Mol. Ther. 2013, 21, 2063-2073.
21. Lamfers, M.; Idema, S.; van Milligen, F.; Schouten, T.; van der Valk, P.; Vandertop, P.; Dirven, C.; Noske, D. Homing properties of adipose-derived stem cells to intracerebral glioma and the effects of adenovirus infection. Cancer Lett. 2009, 274, 78-87.
22. Power, A.T.; Wang, J.; Falls, T.J.; Paterson, J.M.; Parato, K.A.; Lichty, B.D.; Stojdl, D.F.; Forsyth, P.A.; Atkins, H.; Bell, J.C. Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol. Ther. 2007, 15, 123-130.
23. Muthana, M.; Giannoudis, A.; Scott, S.D.; Fang, H.Y.; Coffelt, S.B.; Morrow, F.J.; Murdoch, C.; Burton, J.; Cross, N.; Burke, B.; et al. Use of macrophages to target therapeutic adenovirus to human prostate tumors. Cancer Res. 2011, 71, 1805-1815.
24. Wakimoto, H.; Kesari, S.; Farrell, C.J.; Curry, W.T., Jr.; Zaupa, C.; Aghi, M.; Kuroda, T.; Stemmer-Rachamimov, A.; Shah, K.; Liu, T.C.; et al. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 2009, 69, 3472-3481.
25. Wakimoto, H.; Mohapatra, G.; Kanai, R.; Curry, W.T., Jr.; Yip, S.; Nitta, M.; Patel, A.P.; Barnard, Z.R.; Stemmer-Rachamimov, A.O.; Louis, D.N.; et al. Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. Neuro Oncol. 2012, 14, 132-144.
26. Schaft, N.; Willemsen, R.A.; de Vries, J.; Lankiewicz, B.; Essers, B.W.; Gratama, J.W.; Figdor, C.G.; Bolhuis, R.L.; Debets, R.; Adema, G.J. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes. J. Immunol. 2003, 170, 2186-2194.
27. Willemsen, R.A.; Sebestyén, Z.; Ronteltap, C.; Berrevoets, C.; Drexhage, J.; Debets, R. CD8 alpha coreceptor to improve TCR gene transfer to treat melanoma: Down-regulation of tumor-specific production of IL-4, IL-5, and IL-10. J. Immunol. 2006, 177, 991-998.
28. Schaft, N.; Lankiewicz, B.; Gratama, J.W.; Bolhuis, R.L.; Debets, R. Flexible and sensitive method to functionally validate tumor-specific receptors via activation of NFAT. J. Immunol. Methods 2003, 280, 13-24.
29. Ono, H.A.; Le, L.P.; Davydova, J.G.; Gavrikova, T.; Yamamoto, M. Noninvasive visualization of adenovirus replication with a fluorescent reporter in the E3 region. Cancer Res. 2005, 65, 10154-10158.
30. He, T.C.; Zhou, S.; da Costa, L.T.; Yu, J.; Kinzler, K.W.; Vogelstein, B. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. USA 1998, 95, 2509-2514.
31. De Vrij, J.; van den Hengel, S.K.; Uil, T.G.; Koppers-Lalic, D.; Dautzenberg, I.J.; Stassen, O.M.; Bárcena, M.; Yamamoto, M.; de Ridder, C.M.; Kraaij, R. Enhanced transduction of CAR-negative cells by protein IX-gene deleted adenovirus 5 vectors. Virology 2011, 410, 192-200.
32. Fueyo, J.; Gomez-Manzano, C.; Alemany, R.; Lee, P.S.; McDonnell, T.J.; Mitlianga, P.; Shi, Y.X.; Levin, V.A.; Yung, W.K.; Kyritsis, A.P. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000, 19, 2-12.
33. Fallaux, F.J.; Kranenburg, O.; Cramer, S.J.; Houweling, A.; van Ormondt, H.; Hoeben, R.C.; Van Der Eb, A.J. Characterization of 911: A new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum. Gene Ther. 1996, 7, 215-222.
34. Lamfers, M.L.; Fulci, L.G.; Chiocca, E.A. Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Mol. Ther. 2006, 14, 779-788.
35. Mentel, R.; Döpping, G.; Wegner, U.; Seidel, W.; Liebermann, H.; Döhner, L. Adenovirus-receptor interaction with human lymphocytes. J. Med. Virol. 1997, 51, 252-257.
36. Leon, R.P.; Hedlund, T.; Meech, S.J.; Li, S.; Schaack, J.; Hunger, S.P.; Duke, R.C.; Degregori, A.J. Adenoviral-mediated gene transfer in lymphocytes. Proc. Natl. Acad. Sci. USA 1998, 95, 13159-13164.
37. Yotnda, P.; Onishi, H.; Heslop, H.E.; Shayakhmetov, D.; Lieber, A.; Brenner, M.; Davis, A. Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Ther. 2001, 8, 930-937.
38. Yotnda, P.; Zompeta, C.; Heslop, H.E.; Andreeff, M.; Brenner, M.K.; Marini, F. Comparison of the efficiency of transduction of leukemic cells by fiber-modified adenoviruses. Hum. Gene Ther. 2004, 15, 1229-1242.
39. Shinojima, N.; Hossain, A.; Takezaki, T.; Fueyo, J.; Gumin, J.; Gao, F.; Nwajei, F.; Marini, F.C.; Andreeff, M.; Kuratsu, J.; et al. TGF-beta mediates homing of bone marrow-derived human mesenchymal stem cells to glioma stem cells. Cancer Res. 2013, 73, 2333-2344.
40. Gondi, C.S.; Veeravalli, K.K.; Gorantla, B.; Dinh, D.H.; Fassett, D.; Klopfenstein, J.D.; Gujrati, M.; Rao, J.S. Human umbilical cord blood stem cells show PDGF-D-dependent glioma cell tropism in vitro and in vivo. Neuro Oncol. 2010, 12, 453-465.
41. Lohr, J.; Ratliff, T.; Huppertz, A.; Ge, Y.; Dictus, C.; Ahmadi, R.; Grau, S.; Hiraoka, N.; Eckstein, V.; Ecker, R.C.; et al. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-beta. Clin. Cancer Res. 2011, 17, 4296-308.
42. Huang, J.Y.; Cheng, Y.J.; Lin, Y.P.; Lin, H.C.; Su, C.C.; Juliano, R.; Yang, B.C. Extracellular matrix of glioblastoma inhibits polarization and transmigration of T cells: The role of tenascin-C in immune suppression. J. Immunol. 2010, 185, 1450-1459.
43. Qiao, J.; Wang, H.; Kottke, T.; Diaz, R.M.; Willmon, C.; Hudacek, A.; Thompson, J.; Parato, K.; Bell, J.; Naik, J.; et al. Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. Gene Ther. 2008, 15, 604-616.
44. Kottke, T.; Diaz, R.M.; Kaluza, M.; Pulido, J.; Galivo, F.; Wongthida, P.; Thompson, J.; Willmon, C.; Barber, G.N.; Cheste, J.; et al. Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer. Mol. Ther. 2008, 16, 1910-1918.
45. Zhang, J.G.; Kruse, C.A.; Driggers, L.; Hoa, N.; Wisoff, J.; Allen, J.C.; Zagzag, D.; Newcomb, E.W.; Jadus, M.R. Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy. J. Neurooncol. 2008, 88, 65-76.
46. Zhang, J.G.; Eguchi, J.; Kruse, C.A.; Gomez, G.G.; Fakhrai, H.; Schroter, S.; Ma, W.; Hoa, N.; Minev, B.; Delgado, C.; et al. Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin. Cancer Res. 2007, 13, 566-575.
47. Beier, C.P.; Kumar, P.; Meyer, K.; Leukel, P.; Bruttel, V.; Aschenbrenner, I.; Riemenschneider, M.J.; Fragoulis, A.; Rümmele, P.; Lamszus, K.; et al. The cancer stem cell subtype determines immune infiltration of glioblastoma. Stem Cells Dev. 2012, 21, 2753-2761.
48. Rutledge, W.C.; Kong, J.; Gao, J.; Gutman, D.A.; Cooper, L.A.; Appin, C.; Park, Y.; Scarpace, L.; Mikkelsen, T.; Cohen, M.L.; Aldape, K.D.; et al. Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. Clin. Cancer Res. 2013, 19, 4951-4960.